Bristol-Myers Squibb Company (BMY) will raise its dividend by 2.6 percent to $0.40 quarterly. This marks the 10th consecutive year of dividend increases for the health care company. Last year BMY also hiked its dividend by 2.6 percent.

The next quarterly dividend will be payable on February 1, 2018, to stockholders of record at the close of business on January 5, 2018. The new dividend yield for BMY is 2.6%.

Bristol-Myers Squibb Company is is a global specialty biopharmaceutical company.  Bristol-Myers is developing new medicines in the following core therapeutic areas: oncology with a priority in certain tumor types; immunoscience with priorities in psoriasis, lupus, RA and inflammatory bowel disease;  cardiovascular with a priority in heart disease and; fibrotic disease with priorities in lung and liver. The company's top drugs include Opdivo (infused biologic immuno-oncology treatment) and Eliquis (anticoagulation).